Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation

Justin Laporte, Katelin Jackson, Xu Zhang, Asad Bashey, Lawrence E Morris, Lizamarie Bachier Rodriguez, Melhem M. Solh, Scott R. Solomon, H. Kent Holland

Blood (2024) 144 (Supplement 1): 7333.

https://doi.org/10.1182/blood-2024-200207

Published: 2024

Journal Articles

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Scott R. Solomon, Melissa Sanacore, Lizamarie Bachier Rodriguez, Latasha McCoy, Caitlin Guzowski, Katelin C Jackson, Xu Zhang, H. Kent Holland, Lawrence E Morris, Melhem M. Solh, Asad Bashey

Blood (2024) 144 (Supplement 1): 3528.

https://doi.org/10.1182/blood-2024-199618

Published: 2024

Journal Articles

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Blood (2024) 144 (Supplement 1): 685.

https://doi.org/10.1182/blood-2024-194414

Published: 2024

Journal Articles

Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide

Scott R. Solomon, Melissa Sanacore, Asad Bashey, Katelin C Jackson, Lizamarie Bachier Rodriguez, Lawrence E Morris, H. Kent Holland, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 3501.

https://doi.org/10.1182/blood-2024-200103

Published: 2024

Journal Articles

The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Melhem M. Solh, Asad Bashey, Michael T Aubrey, Brian Freed, Christina Roark, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Scott R. Solomon

Blood (2024) 144 (Supplement 1): 4913.

https://doi.org/10.1182/blood-2024-210329

Published: 2024

Journal Articles

Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

Melhem M. Solh, Asad Bashey, Lawrence E Morris, Lizamarie Bachier-Rodriguez, H. Kent Holland, Xu Zhang, Rajveer Singh, Katelin Jackson, Scott R. Solomon

Blood (2024) 144 (Supplement 1): 4912.

https://doi.org/10.1182/blood-2024-208659

Published: 2024

Journal Articles

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

Asad Bashey, Xu Zhang, H. Kent Holland, Lawrence E Morris, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 1450.

https://doi.org/10.1182/blood-2024-209117

Published: 2024

Journal Articles

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Steven Baker, Asad Bashey, Lizamarie Bachier-Rodriguez, Lawrence E Morris, H Kent Holland, Justin Laporte, Scott R. Solomon, Melissa Sanacore, Melhem Solh

Blood (2024) 144 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2024-210395

Published: 2024

Journal Articles

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center

Asad Bashey, Xu Zhang, Lawrence E Morris, H. Kent Holland, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2024-209199

Published: 2024

Journal Articles

High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Melhem M. Solh, Scott R. Solomon, Christina Roark, Michael T Aubrey, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Brian Freed, Asad Bashey

Blood (2024) 144 (Supplement 1): 4948.

https://doi.org/10.1182/blood-2024-210627

Published: 2024

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

Journal Articles

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Michael T. Aubrey, Christina L. Roark, Lawrence E. Morris, Jr., H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2022) 140 (Supplement 1): 4861–4862.

https://doi.org/10.1182/blood-2022-158759

Published: 2022

Journal Articles

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Rebecca Farley, Eva Karam, Xu Zhang, Asad Bashey, H. Kent Holland, Lawrence E. Morris, Jr., Scott R. Solomon, Melhem Solh

Blood (2022) 140 (Supplement 1): 11694–11695.

https://doi.org/10.1182/blood-2022-167938

Published: 2022

Journal Articles

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, Melhem Solh, Lawrence E. Morris, Jr., H. Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey

Blood (2022) 140 (Supplement 1): 1188–1189.

https://doi.org/10.1182/blood-2022-158797

Published: 2022

Journal Articles

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed, Christina L Roark, Lizamarie Bachier-Rodriguez, Lawrence E. Morris, Jr., H. Kent Holland, Scott R. Solomon

Blood (2022) 140 (Supplement 1): 7738–7739.

https://doi.org/10.1182/blood-2022-164804

Published: 2022

Journal Articles

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, H. Kent Holland, Lawrence E. Morris, Jr., Asad Bashey, Melhem Solh

Blood (2022) 140 (Supplement 1): 7647–7648.

https://doi.org/10.1182/blood-2022-162788

Published: 2022

Journal Articles

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Asad Bashey, Xu Zhang, Scott R. Solomon, Lizamarie Bachier-Rodriguez, H. Kent Holland, Lawrence E. Morris, Jr., Melhem Solh

Blood (2022) 140 (Supplement 1): 7568–7569.

https://doi.org/10.1182/blood-2022-156852

Published: 2022

Journal Articles

Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Asad Bashey, Xu Zhang, Melhem Solh, H. Kent Holland, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, Scott R. Solomon

Blood (2022) 140 (Supplement 1): 11007–11008.

https://doi.org/10.1182/blood-2022-163574

Published: 2022

Journal Articles

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

Melhem Solh, Scott R. Solomon, Xu Zhang, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, H. Kent Holland, Asad Bashey

Blood (2022) 140 (Supplement 1): 4745–4746.

https://doi.org/10.1182/blood-2022-164773

Published: 2022

Journal Articles

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Asad Bashey, Lawrence E. Morris, Jr., H. Kent Holland, Melhem Solh

Blood (2022) 140 (Supplement 1): 10618–10619.

https://doi.org/10.1182/blood-2022-158803

Published: 2022

NARROW

Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide

The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center

High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only